ORR was 7% for anti-PD-1, 0% for anti-CTLA-4, 14% for combination immunotherapy, 53% for TT and 0% for chemotherapy.<h4>Conclusions</h4>Response to first or second-line systemic treatment may be a surrogate for long-term survival patients with advanced melanoma.<h4>Clinical trial identification</h4>Clinicaltrials.gov: NCT03605771. This evidence concerns the gene CTLA4 and melanoma.